RCT: Intermediate-dose enoxaparin (1 mg/kg/d) not better than standard-dose prophylactic anticoagulation in patients with Covid-19 admitted to the intensive care unit

Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinical Trial – JAMA

Editorial: Finding the Optimal Thromboprophylaxis Dose in Patients With COVID-19 – JAMA

Commentary on Twitter

Intermediate-dose prophylactic enoxaparin (1 mg/kg/d) had no effect on a primary composite outcome of adjudicated venous or arterial thrombosis, ECMO, or 30-d mortality vs standard dose enoxaparin among ICU patients w #COVID19 https://t.co/L6UdB31J7V

— JAMA (@JAMA_current) March 18, 2021